Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting
Journal of Gastroenterology · 2025-03 · 60 (3) · 356-367
DOI: 10.1007/s00535-024-02186-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, online erschienen am 30.11.2024. Verfasst von Hiroshi Imaoka und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. hiimaoka@east.ncc.go.jp. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
S-1 monotherapy had previously been widely used as a second-line treatment for pancreatic cancer (PC) after gemcitabine-based chemotherapy mainly in Japan. Based on the results of the NAPOLI-1 trial, the recommended second-line therapy is now liposomal irinotecan plus fluorouracil/folinic acid (nal-IRI + 5-FU/LV). However, there have been no studies comparing nal-IRI + 5-FU/LV therapy with S-1 monotherapy.
Methods
The main objective of this study was to compare overall survival (OS) in patients treated with nal-IRI + 5-FU/LV and those treated with S-1 monotherapy as second-line treatments, using the inverse probability of treatment weighting (IPTW) method. This study was conducted in 31 institutions participating in Japan Oncology Network in Hepatobiliary and Pancreas. To minimize potential biases due to the retrospective design, IPTW analysis was performed with multiple imputation, and imputed IPTW-adjusted hazard ratios and corresponding 95% confidence intervals (CIs) were estimated using a Cox proportional hazards model and combined into pooled estimates.
Results
A total of 463 metastatic PC patients were enrolled in this study (257 in the S-1 monotherapy group and 206 in the nal-IRI + 5-FU/LV group). The median OS was 7.50 months (95% CI 4.18–12.69 months) in the nal-IRI + 5-FU/LV group and 5.72 months (95% CI 2.76–10.79 months) in the S-1 monotherapy group. In the IPTW-adjusted Cox proportional hazards model, nal-IRI + 5-FU/LV was associated with a significant OS benefit (pooled IPTW-adjusted hazard ratio, 0.779; 95% CI 0.399—0.941; p = 0.025).
Conclusion
These findings support the use of nal-IRI + 5-FU/LV as standard second-line treatment for PC patients after gemcitabine-based chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. hiimaoka@east.ncc.go.jp.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.
ORCID-Profile: Hiroshi Imaoka
Zitieren
APA
Imaoka, H., Ikeda, M., Kobayashi, S., Ohba, A., Ueno, M., Suzuki, Y., Tsumura, H., Kimura, N., Kawaguchi, S., Kawamoto, Y., Nakachi, K., Tsuji, K., Kobayashi, N., Ashida, R., Okano, N., Umemoto, K., Murohisa, G., Hosokawa, A., Asagi, A., …, & Japan Oncology Network in Hepatobiliary and Pancreas (2025). Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. Journal of Gastroenterology, 60(3), 356-367. https://doi.org/10.1007/s00535-024-02186-9
Vancouver
Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, et al. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. Journal of Gastroenterology. 2025;60(3):356-367. doi:10.1007/s00535-024-02186-9
BibTeX
@article{Imaoka2025,
author = {Imaoka, Hiroshi and Ikeda, Masafumi and Kobayashi, Satoshi and Ohba, Akihiro and Ueno, Masayuki and Suzuki, Yuko and Tsumura, Hidetaka and Kimura, Nana and Kawaguchi, Shinya and Kawamoto, Yasuyuki and Nakachi, Kohei and Tsuji, Kunihiro and Kobayashi, Noritoshi and Ashida, Reiko and Okano, Naohiro and Umemoto, Kumiko and Murohisa, Gou and Hosokawa, Ayumu and Asagi, Akinori and Nebiki, Hiroko and Suzuki, Rei and Terashima, Takeshi and Shibata, Ryusuke and Kawata, Kazuhito and Doi, Toshifumi and Ohyama, Hiroshi and Kitano, Yohei and Shioji, Kazuhiko and Okuyama, Hiroyuki and Naganuma, Atsushi and Negoro, Yuji and Sakamoto, Yasunari and Shimizu, Satoshi and Morizane, Chigusa and Ueno, Makoto and Furuse, Junji and Nagano, Hiroaki and Japan Oncology Network in Hepatobiliary and Pancreas, Japan Oncology Network in Hepatobiliary and Pancreas},
title = {Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting},
journal = {Journal of Gastroenterology},
year = {2025},
volume = {60},
number = {3},
pages = {356--367},
doi = {10.1007/s00535-024-02186-9}
}
EUVIMED